M-A | Addition of androgen receptor targeted agents to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer. 27 Sep, 2022 | 13:02h | UTC Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis – ESMO Open